WO2014024164A1 - Process for the preparation of pemetrexed and lysin salt thereof - Google Patents
Process for the preparation of pemetrexed and lysin salt thereof Download PDFInfo
- Publication number
- WO2014024164A1 WO2014024164A1 PCT/IB2013/056497 IB2013056497W WO2014024164A1 WO 2014024164 A1 WO2014024164 A1 WO 2014024164A1 IB 2013056497 W IB2013056497 W IB 2013056497W WO 2014024164 A1 WO2014024164 A1 WO 2014024164A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pemetrexed
- salt
- lysine
- acid
- water
- Prior art date
Links
- AIZPFZIKHIJCQX-UHFFFAOYSA-N NC(N1)=Nc([nH]cc2CCc(cc3)ccc3C(O)=O)c2C1=O Chemical compound NC(N1)=Nc([nH]cc2CCc(cc3)ccc3C(O)=O)c2C1=O AIZPFZIKHIJCQX-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention refers to a process for the preparation of pemetrexed and salts thereof, in particular a lysine salt thereof, to said salt as such and to pharmaceutical compositions comprising the same.
- Pemetrexed is normally used in pharmaceutical preparations in the form of disodium salt, specifically the disodium heptahydrate salt is the product marketed by Eli Lilly and Company under the trademark ALIMTA® and it is described in EP1259513.
- Pemetrexed was originally described in EP432677/US5344932.
- the synthesis shown in this patent provides the 2-amino-7H-pyrrolo (2, 3-d) pyrimidin-4- ol as a raw material, the amino group of this derivative is protected with pivaloyl chloride and the product obtained is transformed in two steps in the corresponding 3-iodo derivative.
- the subsequent coupling reaction with dimethyl N-(4- etinilbenzoil)-L-glutamate provides a derivative biarilacetylenic that is converted to pemetrexed by catalytic hydrogenation and subsequent saponification. This procedure, however, is not suitable for industrial application.
- the pemetrexed diacid may also be obtained by following other most recent synthetic procedures among these those reported in U.S. 5,416,21 1 , in EP 9916742 and in 905128/WO CJ Barnett et al., Org. Proc Res & Develop., 1999, 3, 184-188, using industrial syntheses that require the preparation of the intermediate pemetrexed diethyl ester 3 (Scheme I):
- pemetrexed diethyl ester 4 is prepared by reacting the acid 4-(2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo (2, 3-d) pyrimidin-5-yl) ethyl) benzoic, (2), with the L diethyl hydrochloride glutamate in the presence of a condensing agent in N, N-dimethylformamide as solvent.
- This process involves the use of DMF (a solvent with high toxicity) as a solvent of the coupling reaction, and also, even it allows to obtain the pemetrexed with high purity, consists of a long sequence of operations to isolate and purify the pemetrexed diester salt (4) namely, 3 grindings and a crystallization with relative filtrations, consequently reducing the efficiency of the process.
- DMF a solvent with high toxicity
- esters p-toluenesulphonic acid salt is represented by the possible formation of esters by the reaction of p-toluenesulfonic acid with alcohols.
- esters p-toluensulphoonic products are classified as genotoxic alkylating agents and their content must be reduced to very low values (Genotoxic and carcinogenic impurities in drug substances and Products: Recommended Approaches, FDA Guidance for Industry, 2008; Guideline on the Limits of genotoxic Impurities, EMEA/CHMP 2006).
- the pemetrexed diethyl ester (3) is however described in the literature as solid compound: in CJ Barnett et al, Org. Proc Res & Develop., 1999, 3, 184-188, on page 188 the compound 13 is shown with a pf of 169-171 °C; in E.C. Taylor and B.Liu, J. Org. Chem., 2003, 68, 9938-9947, on page 9945 the compound 25a is shown with a pf 84-86°C; in T.Miwa et al, J. Org. Chem., 1993, 58, 1696-1701 , at page 1700, the compound 23a is shown with a pf 131-133°C.
- EP 2409978 is claimed a new process for preparing the pemetrexed diester (3) that allows to eliminate the procedure of synthesis and purification of (4).
- the coupling reaction between the acid (2) and diethyl glutamate is carried out in an aprotic organic solvent, in particular in a mixture of DMF and dichloromethane; at the end of the reaction, the mixture is washed with a basic aqueous solution, the solution is concentrated, added with a polar organic solvent, preferably ethanol and pemetrexed diester (3) is isolated by crystallization.
- Pemetrexed disodium salt employed in pharmaceutical formulations is characterized by a poor stability and shows the formation of degradation impurities, both in the solid state and in solution, in particular related to the effects of oxidative type, which require suitable conditions of handling and packaging in a controlled atmosphere and preclude the use of liquid formulations ready for use.
- aqueous formulations of pemetrexed salts with antioxidants and chelating agents which have greater long-term stability have been reported, but however they show an increase of the degradation products up to values of 1-5%, which is an impurities amount not acceptable on the basis of the ICH guidelines of pharmaceutical products, if not properly qualified.
- Scope of the present invention is to overcome the problems present in the state of the art and refer to the synthesis of pemetrexed and the instability of disodium salt thereof.
- the present invention is based on the discovery that the use of water- alcohol mixtures as a solvent in the coupling reaction (coupling) of the synthesis of pemetrexed allows the precipitation of the intermediate diethyl ester directly in the reaction mixture, without the need of DMF.
- the pemetrexed diethyl ester thus obtained has already a high purity that allows directly its use in subsequent steps of the synthesis of pemetrexed without the need to perform steps of salification, purification and / or washes as is described in the state of the art according to the methods in which DMF is used.
- the inventors of the present invention have observed that the pemetrexed (bi)lysine salt is surprisingly and unexpectedly more stable than the already known disodium salt.
- This greater stability of the bilysine salt involves a considerable technical advantage since they overcome the problems of instability of the active ingredient pemetrexed in handling and storage steps.
- the pemetrexed bilysine salt may be generically referred to as lysine salt as well as the disodium salt may be generically referred to as the sodium salt.
- the acid (2) is previously converted in situ to the corresponding sodium carboxylate or morpholine carboxylate which may be isolated or directly reacted;
- reaction solvent used consists of a hydro-alcoholic mixture of solvents wherein the alcohol is selected from the group: methanol, ethanol, isopropanol, n-propanol;
- a further object of the present invention is an acid-N-[4-[2-(2-amino-4-oxo- 4,7-dihydro-3H-pyrrolo [2, 3-d] pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic (pemetrexed) salt of (bi)lysine of formula (1)
- composition comprising the compound according to formula (1) and/or a crystalline form thereof as above indicated and at least one pharmacologically acceptable excipient.
- Figure I shows the X-ray diffraction spectrum of diethyl ester pemetrexed precipitated from isopropanol/water.
- Figure II shows the X-ray diffraction spectrum of diethyl ester pemetrexed precipitated from ethanol/water/acetone.
- Figure III the DSC (differential scanning calorimetry) profile of pemetrexed diethyl ester precipitated from ethanol/water/acetone.
- Figure IV shows the X-ray diffraction spectrum of pemetrexed diethyl ester crystallized from 2-methyl tetrahydrofuran / ethanol.
- Figure V shows the X-ray diffraction spectrum of pemetrexed diethyl ester crystallized from ethanol/methyl ethyl ketone.
- Figure VI the DSC (differential scanning calorimetry) profile of pemetrexed diethyl ester crystallized from ethanol/methyl ethyl ketone.
- Figure VII shows the X-ray diffraction spectrum of pemetrexed lysine salt.
- Figure VIII shows the data of X-ray diffraction of pemetrexed lysine salt.
- Figure IX shows the DSC (differential scanning calorimetry) profile of the lysine salt.
- the present invention consists of the following aspects, which are described in detail below.
- the process of synthesis object of the present description is a process for the preparation of a pemetrexed salt, of general formula I
- B + is a suitable cation, preferably selected from Na+ or protonated lysine.
- This salt is obtained by a new process of synthesis of industrial applicability (scheme II) that allows to obtain easily the intermediate of synthesis (3), the pemetrexed ethyl diester, in solid state avoiding the use of DMF.
- hydroalcoholic mixtures preferably isopropanol/water
- the use of hydroalcoholic mixtures results in the precipitation of the intermediate (3) from the reaction mixture.
- the pemetrexed diester (3) obtained after filtration has already a high purity ( ⁇ 98%) that allows the direct use of it in subsequent steps without further purification.
- the pemetrexed diester (3) thus prepared can be converted directly into the desired pemetrexed salt, for example the disodium salt of lysine or, without the need to isolate the pemetrexed in free acid form that is essential when preparing the pemetrexed ester salt with p-toluene sulfonic acid, as described in the state of the art.
- the direct formation of the pemetrexed salt without the need to isolate the pemetrexed in acid form represents a further advantage of the process of preparation object of the present invention.
- the pharmaceutically acceptable pemetrexed salts obtainable with the process object of the present invention are, in particular, without being limited to, the disodium salt and the (bi)lysine salt.
- These salts may be either in anhydrous form or in hydrated form.
- said salt comprises a percentage of water comprises in the range 0- 22% by weight. It had to be considered for example that the compound in the market, Alimta®, corresponds to the heptahydrate disodium pemetrexed and contains a percentage of water equal to 21 % by weight, and another pemetrexed salt well known literature, the hemipentahydrate disodium pemetrexed has instead a percentage of water equal to 8.7% by weight.
- the process for the preparation of the salt of formula 1 comprises, in particular, the following steps:
- the process of pemetrexed synthesis object of the present application is characterized mainly by the fact that the reaction solvent used in the synthetic step a) of Scheme I is constituted by a mixture of water and ethanol solvents in which the alcohol is selected from the group methanol, ethanol, isopropanol, n-propanol.
- the solvent mixture is represented by isopropanol/water or water/ethanol.
- the water and isopropyl alcohol or ethyl alcohol are in ratio v/v comprised between 3/1 and 1/3, preferably between 6/4 and 4/6.
- the amount of the solvent mixture used is between 5 and 25 volumes with respect to the acid precursor (2) and preferably between 10 and 20 volumes, meaning by the term "volume" the ratio solvent/solute expressed in ml of solvent/g of precursor.
- the intermediate pemetrexed diethyl ester (3) precipitates directly from the reaction mixture with a purity>98% and can be possibly used directly in the next step without further purification.
- the acid (2) is previously converted in situ into the corresponding sodium carboxylate which can be isolated (US2008/0146799, example 5, p 13) or directly reacted.
- the acid 2 can be converted in situ into the corresponding morpholinium carboxylate which is then reacted directly.
- the salification in situ can be performed according to the usual methods which are known to the skilled person.
- the coupling reagent is selected from CDMT (2-chloro-4 ,6-dimethoxy-
- EDC 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide
- DMTMM (4- (4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4-methylmorpholine chloride) and more preferably CDMT (2-chloro-4 ,6-dimethoxy-1 ,3,5-triazine).
- the reaction takes place at a temperature between 0°C and 60°C, preferably between 15 and 50°C.
- the complete precipitation of pemetrexed diethyl ester (3) is obtained by further addition to the reaction mixture, of 5-35 volumes, preferably 10-25 volumes, of water or a water/acetone mixture in a ratio comprises from 2/1 to 1/1.
- the suspension obtained can be maintained under stirring at temperatures between 0 and 5°C, preferably between 5 and 30°C, for a time between 1 and 24 hours, preferably between 5 and 12 hours.
- the diester pemetrexed (3) thus obtained after filtration and washing with a hydro alcoholic solvents mixture, can be subsequently dried under vacuum at about 50°C up to a constant weight.
- This crude product exhibits high HPLC purity >98% and, for the purposes of the present invention, can be used directly without further purifications in the subsequent reaction of hydrolysis to the free acid.
- the reaction temperature is between 0 and 40°C, preferably between 10 and 30°C.
- the acid (5) is salified with a suitable base, preferably selected from NaOH or lysine to obtain the corresponding pemetrexed salt.
- the process described here can also be used to prepare the pemetrexed disodium salt that may be obtained from the biacid precursor (5), for example, by treatment with sodium hydroxide in aqueous solution up to pH 8 and precipitation with a water miscible solvent in analogy to what is reported in EP 905 128.
- the high purity of diester pemetrexed (3) allows to obtain the disodium salt in a single step directly by basic hydrolysis in a hydro alcoholic solution of (3) and precipitation of the disodium salt by addition of a water miscible solvent.
- the crude diester pemetrexed can be used without further purification in subsequent reactions or may be further purified, for example, for a better characterization, by crystallization using a series of solvents selected from acetonitrile, ethyl acetate / ethanol, 2-methyl tetrahydrofuran/ethanol, methyl ethyl ketone/ethanol, isopropanol/water, yielding a pemetrexed diethyl ester (3) with a purity > 99.5%, as shown by HPLC.
- Object of the present invention is also the acid compound acid N-[4 - [2 - (2- amino-4-oxo-4 ,7-dihydro-3H-pyrrolo [2, 3-d] pyrimidin-5-yl) ethyl] benzoyl]-L- glutamic (pemetrexed) lysine salt of formula (1)
- this salt has a percentage of water comprises in the range 0- 22% by weight.
- the lysine salt can be obtained as crystalline solid and is characterized by X-ray diffraction spectrum shown in Figure VII, and summarized in Figure VIII.
- the lysine salt is also characterized by a profile DSC (differential scanning calorimetry) shown in Figure IX, wherein has a melting point at 230°C followed by decomposition.
- the thermogravimetric analysis (TGA) shows a weight loss of 3.8%.
- the pemetrexed lysine salt object of the present application is characterized by a significantly higher stability compared to the disodium salt as shown in the following tables.
- Table 1 Results of HPLC purity (area%) for pemetrexed hemipentahydrate disodium salt stored at 25°C ⁇ 5°C and 40°C ⁇ 5°C (humidity not controlled)
- Table 3 Results of the H PLC purity (area %) for the pemetrexed hemipentahydrate disodium salt, heptahydrate and lysine salt stored at 100°C for 6 days (humidity not controlled)
- the pemetrexed disodium salt shows a significant degradation in accelerated conditions at 40°C, and the formation of 3 main impurities in relative retention times of 0: 19, 0:26 and 1 : 15 has already observed after 3 months. In the same conditions the lysine salt is practically unaltered.
- the main degradation products were identified by HPLC/MS and these structures appear to be attributable to oxidation of the product.
- a similar pattern of impurities is obtained by treatment of pemetrexed disodium salt in aqueous solution in the presence of oxidizing agents such as hydrogen peroxide 10%.
- the lysine salt is also much more stable under stress conditions of 100°C for 6 days and the same impurities do not exceed the value of 0.2%.
- the pemetrexed lysine salt as also its crystalline form defined by x-ray diffraction spectrum of Figure VII, is advantageously usable as a medicament and preferably, similarly to the pemetrexed disodium salt, as anti-tumour drug.
- the pemetrexed lysine salt can be obtained in general through a passage of salification of pemetrexed biacid (5) with the base lysine.
- the salt of formula I can be obtained by adding to an aqueous solution of pemetrexed acid (5) from 2 to 4 equivalents of lysine hydrate, preferably 3 equivalents.
- the lysine salt formed is precipitated from the reaction mixture by addition of a water miscible solvent such as acetone, ethanol, methanol or isopropanol, preferably ethanol.
- the volumes of water are between 3 and 8 with respect to the acid precursor and preferably 5 volumes, the volumes of the organic solvent are between 18 e 48 volumes compared to the acid precursor, preferably 30 volumes meaning with the term "volume" the ratio solvent/solute in ml of solvent/g of precursor.
- compositions of the present invention are compositions/formulations comprising the pemetrexed lysine salt of formula 1 or its crystalline form defined by the spectrum of Figure 3 and one or more pharmaceutically acceptable excipients. Said compositions are primarily intended for use as anti-tumour.
- compositions described herein are preferably administered by oral, parenteral or intravenous route and, in any case, according to all the routes of administration known to those skilled in the art and suitable to achieve the target site of pharmacological interest.
- compositions for oral administration may take the form of liquid solutions or suspensions or powders.
- the compositions may be presented in unit dosage form in order to facilitate the administration.
- Each unit dose contains a predetermined amount of active ingredient calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- Typical unit dosage forms include pills, tablets, capsules or the like in the case of solid compositions and vials or syringes in the case of liquid compositions.
- the active ingredient(s) is mixed with at least one inert pharmaceutically acceptable excipient or carrier and usual additives.
- compositions for parenteral use may be, for example, solutions, aqueous or oil suspensions or emulsions and can be formulated according to the known art using suitable dispersing agents, wetting agents and suspending agents.
- preservatives may also be present preservatives and other additives such as antimicrobial, anti-oxidants, chelating agents and inert gases (Mack (1982) Remington's Pharmaceutical Sciences, 16th Edition).
- compositions of the present invention may also be lyophilized for storage and reconstituted in a suitable carrier prior to use.
- Pemetrexed disodium or lysine salt 25 mg/ml (as pemetrexed acid) Mannitol : 25 mg/ml
- the product has the X-ray diffraction spectrum shown in Figure I and corresponds to a partially amorphous product. Depending on the different batches of reaction compounds in lesser degree of crystallinity can be obtained.
- the reaction mixture is kept under stirring at 40°C for 3 hours and is filtered on a bed consisting of 0,48 g of activated carbon and 0:48 g of Celite. After washing the filter with 20 ml of ethanol/water mixture 3/2, the filtrate is heated to 40°C and added to 49 ml of water and 55 ml of Acetone.
- An analogous compound can be obtained by crystallization from the following solvents: ethanol, ethyl acetate/ethanol, acetonitrile
- the suspension is filtered and the solid dried under vacuum at 50°C.
- the light pink product is heated to reflux in 65 ml of DMSO and 260 ml of absolute ethanol for 1.5 hours. After cooling at 10°C the suspension is filtered and the wet solid is triturated at 5°C with 250 ml of absolute ethanol for 30'. The solid is dried under vacuum at 50°C to give 12.2 g of a light pink solid (Yield 79%).
- a suspension of 9.60 g of the product (3) obtained in Example 6 (or alternatively one of Examples 7-12) in 62 ml of 1 M NaOH is kept under stirring at room temperature for about 1 hour.
- the solution is acidified to pH 3 with 4M HCI and the mixture is heated to 70-75°C for about 20'.
- the suspension obtained is cooled at room temperature and filtered.
- the wet solid is triturated with 93 ml of ethanol/water 1/1 at room temperature for 2 hours. After filtration, the solid is dried under vacuum at 50°C to give 6.15 g of off-white solid (98% yield).
- Pemetrexed (5) 8.8 g of Pemetrexed (5) are added to a solution of 9 g of lysine hydrate in 41 ml of water. The solution is heated to 70°C and added to 249 ml of ethanol. The suspension is allowed to cool to room temperature, filtered and the solid is dried at 50°C.
- the samples were packed in glass containers in air or alternatively in a controlled atmosphere.
- the purity of the samples was determined at varying time intervals (1 , 3, 6 months for samples stored at 25°C ⁇ 5°C and 45°C ⁇ 5°C, 6 days for samples stored at 100°C ) by HPLC analysis using the following procedure:
- mannitol and water (water for injection-WFI) are charged in order to have a solution consisting of 25 mg/ml of pemetrexed acid, 25 mg/ml of mannitol.
- the pH of the solution obtained is adjusted to 7.2 ⁇ 0.6 with 0.1 N NaOH or HCI 0.1 N.
- the solution is then filtered twice on 0,22 ⁇ , added to vials, in the required quantity and lyophilized.
- the pemetrexed lysine salt (1), mannitol and water (water for injection-WFI) are charged in order to have a solution consisting of 25 mg/ml of pemetrexed acid, 25 mg/ml of mannitol.
- the pH of the solution obtained is adjusted to 7.2 ⁇ 0.6 with 0.1 N NaOH or HCI 0.1 N.
- the solution is then filtered twice on 0,22 ⁇ , added to in vials, in the required quantity and lyophilized.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013301156A AU2013301156B2 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
LTEP13777144.0T LT2882753T (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
DK13777144.0T DK2882753T3 (en) | 2012-08-08 | 2013-08-08 | PROCEDURE FOR PREPARING PEMETREXED AND LYSSEAL SALES THEREOF |
MX2015001712A MX362858B (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof. |
BR112015002429A BR112015002429A8 (en) | 2012-08-08 | 2013-08-08 | process for preparing pemetrexed and lysine salt from this |
CN201380041935.8A CN104736540B (en) | 2012-08-08 | 2013-08-08 | The preparation method of pemetrexed and its lysine salt |
IN833DEN2015 IN2015DN00833A (en) | 2012-08-08 | 2013-08-08 | |
RU2015108042A RU2609006C2 (en) | 2012-08-08 | 2013-08-08 | Process for preparation of pemetrexed and lysin salt thereof |
EP13777144.0A EP2882753B1 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
SI201330427A SI2882753T1 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
RS20161202A RS55515B1 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
KR1020157005932A KR102288417B1 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
ES13777144.0T ES2607890T3 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysine salt thereof |
ZA2015/01549A ZA201501549B (en) | 2012-08-08 | 2015-03-06 | Process for the preparation of pemetrexed and lysin salt thereof |
HK15110234.8A HK1209426A1 (en) | 2012-08-08 | 2015-10-19 | Process for the preparation of pemetrexed and lysin salt thereof |
CY20161101351T CY1118514T1 (en) | 2012-08-08 | 2016-12-28 | METHOD FOR PREPARING PERMETREXIDIS AND SOLUTION SALT |
SM201600474T SMT201600474B (en) | 2012-08-08 | 2016-12-28 | PROCEDURE FOR THE PREPARATION OF PEMETREXED AND ITS LISINE SALT |
HRP20170011TT HRP20170011T1 (en) | 2012-08-08 | 2017-01-05 | Process for the preparation of pemetrexed and lysin salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000398A ITRM20120398A1 (en) | 2012-08-08 | 2012-08-08 | PEMETREXED SYNTHESIS PROCESS AND ITS LYSINE SALT. |
ITRM2012A000398 | 2012-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014024164A1 true WO2014024164A1 (en) | 2014-02-13 |
Family
ID=47018368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/056497 WO2014024164A1 (en) | 2012-08-08 | 2013-08-08 | Process for the preparation of pemetrexed and lysin salt thereof |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP2882753B1 (en) |
KR (1) | KR102288417B1 (en) |
CN (1) | CN104736540B (en) |
AU (1) | AU2013301156B2 (en) |
BR (1) | BR112015002429A8 (en) |
CY (1) | CY1118514T1 (en) |
DK (1) | DK2882753T3 (en) |
ES (1) | ES2607890T3 (en) |
HK (1) | HK1209426A1 (en) |
HR (1) | HRP20170011T1 (en) |
HU (1) | HUE032304T2 (en) |
IN (1) | IN2015DN00833A (en) |
IT (1) | ITRM20120398A1 (en) |
LT (1) | LT2882753T (en) |
MX (1) | MX362858B (en) |
PL (1) | PL2882753T3 (en) |
PT (1) | PT2882753T (en) |
RS (1) | RS55515B1 (en) |
RU (1) | RU2609006C2 (en) |
SI (1) | SI2882753T1 (en) |
SM (1) | SMT201600474B (en) |
TW (1) | TWI609017B (en) |
WO (1) | WO2014024164A1 (en) |
ZA (1) | ZA201501549B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107641124A (en) * | 2016-07-22 | 2018-01-30 | 上海创诺制药有限公司 | A kind of pemetrexed diacid novel crystal forms and preparation method thereof |
CN109836425B (en) * | 2017-11-24 | 2023-01-24 | 江苏创诺制药有限公司 | Preparation process of synthetic pemetrexed |
CN110128427A (en) * | 2018-02-09 | 2019-08-16 | 鲁南制药集团股份有限公司 | Pemetrexed valine salt |
CN110128428A (en) * | 2018-02-09 | 2019-08-16 | 鲁南制药集团股份有限公司 | Pemetrexed alanine salt |
CN110128426B (en) * | 2018-02-09 | 2021-12-14 | 鲁南制药集团股份有限公司 | Pemetrexed glutamate |
CN111333658A (en) * | 2020-05-06 | 2020-06-26 | 贵州联科中贝制药科技有限公司 | Preparation method of pemetrexed disodium hydrate |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005128A1 (en) | 1988-10-31 | 1990-05-17 | Mitsui Toatsu Chemicals, Inc. | Process for preparing organic group-substituted sodium aluminum hydride |
EP0432677A1 (en) | 1989-12-11 | 1991-06-19 | The Trustees Of Princeton University | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives |
EP0589720A2 (en) * | 1992-09-25 | 1994-03-30 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
US5344932A (en) | 1989-12-11 | 1994-09-06 | Trustees Of Princeton University | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
US5416211A (en) | 1992-09-25 | 1995-05-16 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
EP0905128A1 (en) | 1997-09-26 | 1999-03-31 | Eli Lilly And Company | Processes and intermediates useful to make antifolates |
EP0991674A2 (en) | 1997-06-18 | 2000-04-12 | Basf Aktiengesellschaft | Cyclopenta[i]phenanthrene metal complex catalyst systems |
EP1259513A2 (en) | 2000-02-25 | 2002-11-27 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
US20080146799A1 (en) | 2006-08-14 | 2008-06-19 | Nicola Diulgheroff | Processes for preparing intermediates of pemetrexed |
EP2301909A1 (en) | 2008-05-30 | 2011-03-30 | Shanghai Cdymax Pharmaceuticals Co., Ltd | Processes for preparing pemetrexed disodium and its intermediate,4-(4-carbomethoxyphenyl)butanal |
EP2409978A2 (en) | 2010-07-22 | 2012-01-25 | Chemi SPA | A novel process for the synthesis of pemetrexed disodium salt |
WO2012015810A2 (en) | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
WO2012056285A1 (en) * | 2010-10-25 | 2012-05-03 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of pemetrexed |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1934226A2 (en) * | 2006-08-14 | 2008-06-25 | Sicor, Inc. | Highly pure pemetrexed diacid and processes for the preparation thereof |
-
2012
- 2012-08-08 IT IT000398A patent/ITRM20120398A1/en unknown
-
2013
- 2013-08-06 TW TW102128058A patent/TWI609017B/en active
- 2013-08-08 EP EP13777144.0A patent/EP2882753B1/en active Active
- 2013-08-08 RU RU2015108042A patent/RU2609006C2/en active
- 2013-08-08 WO PCT/IB2013/056497 patent/WO2014024164A1/en active Application Filing
- 2013-08-08 RS RS20161202A patent/RS55515B1/en unknown
- 2013-08-08 MX MX2015001712A patent/MX362858B/en active IP Right Grant
- 2013-08-08 PT PT137771440T patent/PT2882753T/en unknown
- 2013-08-08 DK DK13777144.0T patent/DK2882753T3/en active
- 2013-08-08 PL PL13777144T patent/PL2882753T3/en unknown
- 2013-08-08 CN CN201380041935.8A patent/CN104736540B/en active Active
- 2013-08-08 ES ES13777144.0T patent/ES2607890T3/en active Active
- 2013-08-08 AU AU2013301156A patent/AU2013301156B2/en active Active
- 2013-08-08 KR KR1020157005932A patent/KR102288417B1/en active IP Right Grant
- 2013-08-08 IN IN833DEN2015 patent/IN2015DN00833A/en unknown
- 2013-08-08 BR BR112015002429A patent/BR112015002429A8/en not_active Application Discontinuation
- 2013-08-08 LT LTEP13777144.0T patent/LT2882753T/en unknown
- 2013-08-08 SI SI201330427A patent/SI2882753T1/en unknown
- 2013-08-08 HU HUE13777144A patent/HUE032304T2/en unknown
-
2015
- 2015-03-06 ZA ZA2015/01549A patent/ZA201501549B/en unknown
- 2015-10-19 HK HK15110234.8A patent/HK1209426A1/en unknown
-
2016
- 2016-12-28 SM SM201600474T patent/SMT201600474B/en unknown
- 2016-12-28 CY CY20161101351T patent/CY1118514T1/en unknown
-
2017
- 2017-01-05 HR HRP20170011TT patent/HRP20170011T1/en unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005128A1 (en) | 1988-10-31 | 1990-05-17 | Mitsui Toatsu Chemicals, Inc. | Process for preparing organic group-substituted sodium aluminum hydride |
EP0432677A1 (en) | 1989-12-11 | 1991-06-19 | The Trustees Of Princeton University | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives |
US5344932A (en) | 1989-12-11 | 1994-09-06 | Trustees Of Princeton University | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
EP0589720A2 (en) * | 1992-09-25 | 1994-03-30 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
US5416211A (en) | 1992-09-25 | 1995-05-16 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
EP0991674A2 (en) | 1997-06-18 | 2000-04-12 | Basf Aktiengesellschaft | Cyclopenta[i]phenanthrene metal complex catalyst systems |
EP0905128A1 (en) | 1997-09-26 | 1999-03-31 | Eli Lilly And Company | Processes and intermediates useful to make antifolates |
EP1259513A2 (en) | 2000-02-25 | 2002-11-27 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
US20080146799A1 (en) | 2006-08-14 | 2008-06-19 | Nicola Diulgheroff | Processes for preparing intermediates of pemetrexed |
EP2301909A1 (en) | 2008-05-30 | 2011-03-30 | Shanghai Cdymax Pharmaceuticals Co., Ltd | Processes for preparing pemetrexed disodium and its intermediate,4-(4-carbomethoxyphenyl)butanal |
EP2409978A2 (en) | 2010-07-22 | 2012-01-25 | Chemi SPA | A novel process for the synthesis of pemetrexed disodium salt |
WO2012015810A2 (en) | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
WO2012056285A1 (en) * | 2010-10-25 | 2012-05-03 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of pemetrexed |
Non-Patent Citations (10)
Title |
---|
"Genotoxic and carcinogenic impurities in drug substances and Products: Recommended Approaches", FDA GUIDANCE FOR INDUSTRY, 2008 |
"Guideline on the Limits of genotoxic Impurities", EMEA/CHMP, 2006 |
BARNETT C J ET AL: "A PRACTICAL SYNTHESIS OF MULTITARGETED ANTIFOLATE LY231514", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 3, no. 3, 1 January 1999 (1999-01-01), pages 184 - 188, XP000982091, DOI: 10.1021/OP9802172 * |
CJ BARNETT ET AL., ORG. PROC RES & DEV., vol. 3, 1999, pages 184 - 188 |
CJ BARNETT ET AL., ORG. PROC RES & DEVELOP., vol. 3, 1999, pages 184 - 188 |
E.C. TAYLOR; B.LIU, J.ORG. CHEM., vol. 68, 2003, pages 9938 - 9947 |
EDWARD C. TAYLOR ET AL: "A New and Efficient Synthesis of Pyrrolo 2,3- d |pyrimidine Anticancer Agents: Alimta (LY231514, MTA), Homo-Alimta, TNP-351, and Some Aryl 5-Substituted Pyrrolo 2,3- d |pyrimidines", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 68, no. 26, 1 December 2003 (2003-12-01), pages 9938 - 9947, XP055002811, ISSN: 0022-3263, DOI: 10.1021/jo030248h * |
MACK: "Remington's Pharmaceutical Sciences, 16th Edition", 1982 |
MIWA TETSUO ET AL: "A novel synthetic approach to pyrrolo(2,3-d)pyrimidine antifolates", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 58, no. 7, 1 January 1993 (1993-01-01), pages 1696 - 1701, XP002482880, ISSN: 0022-3263, DOI: 10.1021/JO00059A016 * |
T.MIWA ET AL., J.ORG. CHEM., vol. 58, 1993, pages 1696 - 1701 |
Also Published As
Publication number | Publication date |
---|---|
RS55515B1 (en) | 2017-05-31 |
MX362858B (en) | 2019-02-20 |
CY1118514T1 (en) | 2017-07-12 |
AU2013301156B2 (en) | 2017-08-31 |
ZA201501549B (en) | 2016-01-27 |
KR102288417B1 (en) | 2021-08-11 |
EP2882753B1 (en) | 2016-10-05 |
HK1209426A1 (en) | 2016-04-01 |
ES2607890T3 (en) | 2017-04-04 |
IN2015DN00833A (en) | 2015-06-12 |
KR20150045458A (en) | 2015-04-28 |
LT2882753T (en) | 2016-12-12 |
BR112015002429A2 (en) | 2017-07-04 |
RU2609006C2 (en) | 2017-01-30 |
RU2015108042A (en) | 2016-09-27 |
CN104736540A (en) | 2015-06-24 |
TW201412741A (en) | 2014-04-01 |
SI2882753T1 (en) | 2017-02-28 |
AU2013301156A1 (en) | 2015-02-05 |
ITRM20120398A1 (en) | 2014-02-09 |
DK2882753T3 (en) | 2017-01-16 |
HRP20170011T1 (en) | 2017-03-10 |
SMT201600474B (en) | 2017-03-08 |
HUE032304T2 (en) | 2017-09-28 |
MX2015001712A (en) | 2015-08-14 |
CN104736540B (en) | 2017-08-25 |
TWI609017B (en) | 2017-12-21 |
PT2882753T (en) | 2016-12-27 |
BR112015002429A8 (en) | 2019-07-30 |
PL2882753T3 (en) | 2017-04-28 |
EP2882753A1 (en) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013301156B2 (en) | Process for the preparation of pemetrexed and lysin salt thereof | |
US8258327B2 (en) | Crystalline minocycline base and processes for its preparation | |
ES2730942T3 (en) | Triazolopyridine derivatives as modulators of TNF activity | |
US8481730B2 (en) | Method of synthesis of Bosentan, its polymorphic forms and its salts | |
AU2011215250B2 (en) | Salt of fused heterocyclic derivative and crystal thereof | |
KR101710740B1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
EP2688888B1 (en) | Process for the production of disodium pemetrexed | |
KR20170102204A (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
KR101827444B1 (en) | Crystalline acid-added salt of tircyclo derivatives compound or hydrate thereof and preparation thereof | |
JP7068402B2 (en) | Method for producing thiazole derivative | |
FI57589C (en) | REFERENCE TO A FRAME TRACTOR 6-SUBSTITUTE 3-CARBETOXYHYDRAZINOPYRIDAZINER | |
CN113788835B (en) | Triazole tetrazine compound containing morpholine and quinoline ring and preparation method and application thereof | |
JPH0812676A (en) | 2-((pyridyl-substituted)thio)-carbapenem derivative | |
WO2012001357A1 (en) | Crystalline form of prulifloxacin and processes for its preparation | |
JP2012500268A (en) | Process for the preparation of polymorphs of 7-chloro-N, N, 5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino [4,5-b] indole-1-acetamide | |
JPH09286728A (en) | 2-dimethyl-dihydrobenzopyran-6-propenoic acid derivative | |
EP2647636A1 (en) | Method for producing maleate using wet crystal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13777144 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013301156 Country of ref document: AU Date of ref document: 20130808 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/001712 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157005932 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013777144 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013777144 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015108042 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015002429 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/1202 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: 112015002429 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150203 |